Prospective pilot trial of calcipotriene as a novel topical treatment for acute skin graft versus host disease.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
06
12
2019
accepted:
04
12
2020
pubmed:
10
1
2021
medline:
1
7
2021
entrez:
9
1
2021
Statut:
ppublish
Résumé
Skin graft versus host disease (GVHD) can affect quality of life in hematopoietic stem cell transplant recipients. Therapeutic options for steroid-refractory GVHD are limited. We report the first prospective pilot study evaluating the topical vitamin D3 analog Calcipotriene (DOVONEX 0.005% cream) for acute skin GVHD in children, with associated analyses of target organ chemokine CXCL10 changes in response to therapy. We observed that Calcipotriene applications were safe and well tolerated. There were no symptom progression nor new symptoms requiring GVHD therapy escalation during study period. The most consistent response observed by study subjects was resolution of pruritus in eight patients and significant improvement in pruritus in two study subjects. Nine of ten patients had improvement or resolution of skin rash. In addition, we documented reduction of CXCL10 levels in the skin of seven subjects with GVHD after Calcipotriene course using non-invasive D-Squame® disc application to the skin for chemokine analysis. Our pilot study shows promising observation that topical Calcipotriene could be a novel therapeutic option for acute skin GVHD, especially in patients presenting with pruritus and should be studied in larger prospective studies.
Identifiants
pubmed: 33420390
doi: 10.1038/s41409-020-01189-3
pii: 10.1038/s41409-020-01189-3
pmc: PMC8189900
doi:
Substances chimiques
calcipotriene
143NQ3779B
Calcitriol
FXC9231JVH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1441-1444Références
Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood. 2014;124:363–73. https://doi.org/10.1182/blood-2014-01-514786 . e-pub ahead of print 2014/06/11.
doi: 10.1182/blood-2014-01-514786
pubmed: 24914140
pmcid: 4102709
Wallace G, Myers KC, Teusink-Cross A, Davies SM, Khandelwal P, Jodele S. Topical vitamin D analog for chronic graft versus host disease of the skin. Bone Marrow Transpl. 2018;53:628–33. https://doi.org/10.1038/s41409-017-0031-2 . e-pub ahead of print 2018/01/18.
doi: 10.1038/s41409-017-0031-2
Maestro MA, Molnar F, Carlberg C. Vitamin D and its synthetic analogs. J. Med. Chem. 2019. https://doi.org/10.1021/acs.jmedchem.9b00208 .
Katayama I, Miyazaki Y, Nishioka K. Topical vitamin D3 (tacalcitol) for steroid-resistant prurigo. Br J Dermatol. 1996;135:237–40. e-pub ahead of print 1996/08/01.
doi: 10.1111/j.1365-2133.1996.tb01153.x
Khandelwal P, Smiley K, Fieno AM, Grant RA, Davies SM. CXCL10 can be detected non-invasively from the skin of children with acute skin GvHD. Bone Marrow Transpl. 2016;51:1379–81. https://doi.org/10.1038/bmt.2016.119 . e-pub ahead of print 2016/05/10.
doi: 10.1038/bmt.2016.119
Reichrath J, Muller SM, Kerber A, Baum HP, Bahmer FA. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol. 1997;36:19–28. e-pub ahead of print 1997/01/01.
doi: 10.1016/S0190-9622(97)70320-7
Ikeda U, Wakita D, Ohkuri T, Chamoto K, Kitamura H, Iwakura Y, et al. 1alpha,25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells. Immunol Lett. 2010;134:7–16. https://doi.org/10.1016/j.imlet.2010.07.002 . e-pub ahead of print 2010/07/27.
doi: 10.1016/j.imlet.2010.07.002
pubmed: 20655952
Vanherwegen AS, Cook DP, Ferreira GB, Gysemans C, Mathieu C. Vitamin D-modulated dendritic cells delay lethal graft-versus-host disease through induction of regulatory T cells. J steroid Biochem Mol Biol. 2019;188:103–10. https://doi.org/10.1016/j.jsbmb.2018.12.013 . e-pub ahead of print 2019/01/04.
doi: 10.1016/j.jsbmb.2018.12.013
pubmed: 30605776
Reinhardt-Heller K, Hirschberg I, Lang P, Vogl T, Handgretinger R, Bethge WA, et al. Increase of intermediate monocytes in graft-versus-host disease: correlation with MDR1(+)Th17.1 levels and the effect of prednisolone and 1alpha,25-Dihydroxyvitamin D3. Biol Blood Marrow Transpl. 2017;23:2057–64. https://doi.org/10.1016/j.bbmt.2017.08.008 . e-pub ahead of print 2017/08/16.
doi: 10.1016/j.bbmt.2017.08.008
Miller J, Gallo RL. Vitamin D and innate immunity. Dermatologic Ther. 2010;23:13–22. https://doi.org/10.1111/j.1529-8019.2009.01287.x . e-pub ahead of print 2010/02/09.
doi: 10.1111/j.1529-8019.2009.01287.x
Scolletta S, Colletti M, Di Luigi L, Crescioli C. Vitamin D receptor agonists target CXCL10: new therapeutic tools for resolution of inflammation. Mediators Inflamm. 2013;2013:876319 https://doi.org/10.1155/2013/876319 . e-pub ahead of print 2013/05/22.
doi: 10.1155/2013/876319
pubmed: 23690671
pmcid: 3652186
Baeke F, Korf H, Overbergh L, Verstuyf A, Thorrez L, Van Lommel L, et al. The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation. J Immunol. 2011;186:132–42. https://doi.org/10.4049/jimmunol.1000695 . e-pub ahead of print 2010/12/07.
doi: 10.4049/jimmunol.1000695
pubmed: 21131424